

Revision date: 02-01-2017

SAFETY DATA SHEET

SECTION 1: IDENTIFICATION			
Nephron Pharmaceuticals Corporation 4500 12 th Street Extension West Columbia, SC 29172-3025		(803) 569-2800 (800) 443-4313 (24 hour contact)	
PRODUCT NAME: COMMON NAME: CHEMICAL NAME:	Ipratropium Bromide Inhalation Solution, 0.029 Ipratropium Bromide 8-azoniabicyclo[3.2.1]-octane,3-(3-hydroxy-10 ,bromide, monohydrate (endo,syn)-,(±)	% oxo-2-phenylpropoxy)-8-methl-8-(1-methylethyl)-	
INN: SUBSTANCE CLASS: INTENDED USE:	Ipratropium Bromide Pharmaceutical Use for Inhalation		

SECTION 2: HAZARD(S) IDENTIFICATION

Carcinogenicity: (NTP) No (IARC) No (OSHA) No

Eye: No known significant effects or critical hazards, may cause irritation.

Skin: No known significant effects or critical hazards, may cause irritation.

Ingestion: No known significant effects or critical hazards.

Inhalation: No known significant effects or critical hazards, may cause respiratory irritation.

Chronic Effects: No known significant effects or critical hazards.

Target Organs: No known significant effects or critical hazards.

Medical Conditions Aggravated by long Exposure: No known significant effects or critical hazards.

(See Section 11, "Toxicological Information")

SECTION 3: COMPOSITON / INFORMATION ON INGREDIENTS

NAME: Ipratropium Bromide CAS#: 22254-24-6 % w/v 0.02% **GW** Limits Not Established Other Limits: Not Established Name: Water for Injection CAS# 7732-18-5 99.98% % w/v **SECTION 4: FIRST AID MEASURES** Flush with large amounts of cool water for at least 15 minutes. Obtain medical attention. If In Eyes: If On Skin: Wash affected areas with soap and water after removing contaminated clothing. Obtain medical attention if contamination is significant and/or a skin reaction is evident. If Inhaled: If not breathing, give artificial respiration or CPR. If breathing is difficult, give oxygen. Obtain medical attention and remove to fresh air. Flush mouth out with water. Never give anything by mouth or induce vomiting if unconscious or If Ingested: having convulsions. Obtain medical attention. Page 1 of 4 Safety Data Sheet Nephron Pharmaceuticals Corporation

SECTION 5: FIRE FIGHTING MEASURES

FLASH POINT/TEST METHOD:	Unknown.
LEL/UEL:	Unknown.
SPECIAL PROPERTIES RELATED TO FIRE HAZARD:	None.
STORAGE OR HANDLING CONDITIONS TO BE AVOIDED:	Extreme Heat.
EXTINGUISHING MEDIA:	Water Spray, Multipurpose Dry Chemical, carbon dioxide, and foam for surrounding fire and materials.
FIRE-FIGHTING PROCEDURES:	Wear full protective clothing and use self-contained breathing apparatus (SCBA). Use water spray to keep fire exposed containers cool.

SECTION 6: ACCIDENTAL RELEASE MEASURES

SPILL RESPONSE PROCEDURES (Liquid, Solid, Gas/Vapor):

Protective equipment may be necessary for spills, (See Section 8, "Exposure Controls / Personal Protection" for guidance).

Use personal protective equipment. Contain the spill to prevent drainage into sewers, drains or streams. Use absorbent materials to solidify the spill. Shovel or scoop up solidified waste. Dispose of material according to Federal, State and Local regulations.

SECTION 7: HANDLING AND STORAGE		
HANDLING:	No special protective equipment or procedures are required in the clinical or home environment, Wash thoroughly after handling.	
STORAGE	Protect from light. Store between 50° and 86° F. Discard if solution becomes discolored	

STORAGE: Protect from light, Store between 59° and 86° F. Discard if solution becomes discolored.

SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION

ENGINEERING CONTROLS: In manufacturing plant, provide adequate ventilation for the raw material handling and compounding process which will maintain the dust and vapor levels below the TLV, STEL, and PEL values for the ingredients. Ventilation fans should be explosion proof. Use adequate personal protective equipment e.g. NIOSH-approved respirators, goggles or safety glasses, gloves and protective clothing. Ensure training in the handling of chemical material and use current Safety Data Sheets.

PERSONAL PROTECTION:

Respiratory:	Not required under normal conditions of therapeutic use. See Section 5 " Fire- Fighting Measures" for respiratory protection in the event of a fire.
Eye:	Not required for recommended dosage and administration. Workers should wear goggles or adequate eye protection if splash hazard exists.
Clothing:	Adequate protective clothing should be worn to prevent occupational skin contact.
Gloves:	When routine handling or spill cleanup may result in skin contact, impermeable (e.g., latex) gloves should be worn.
Work Practices:	Special care should be taken to ensure that contaminated clothing, equipment and work surfaces are properly cleaned after use. Wash hands and other areas of skin contact thoroughly with soap and water after handling this material. Contaminated clothing should be cleaned or disposed of. Release rinse water into an approved wastewater system according to Federal,State and Local regulations.
	SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE AND ODOR:	Clear, colorless solution with little or no odor.	
PHYSICAL STATE:	Liquid Solution	
Safety Data Sheet	Page 2 of 4	Nephron Pharmaceuticals Corporation

Effective	Date:	02-01-2017
-----------	-------	------------

MELTING POINT:	Not determined.		
BOILING POINT:	Not determined.		
SOLUBILITY/MISCIBILITY (%w/v):	Water soluble		
SE	ECTION 10: ST	ABILITY AND REACTIVITY	
CHEMICAL STABILITY:		Stable.	
CONDITIONS TO AVOID:		None known.	
INCOMPATIBILITY WITH OTHER MATE	RIALS:	lodine	
HAZARDOUS DECOMPOSITION PROD emits toxic fumes of bromide.	UCTS:	When heated to decomposition	or under fire conditions, material
SEC	TION 11: TOXI	COLOGICAL INFORMATION	
Toxicological information refers to raw substantially reduced in the product. Fe	or more detailed	I information see the SDS on ra	
SE	CTION 12: EC	OLOGICAL INFORMATION	
ENVIRONMENTAL FATE:	Not known		
ENVIRONMENTAL EFFECTS:	Not known		
ENVIRONMENTAL TEST RESULTS:	N/A		
SE		POSAL CONSIDERATIONS	
ROUTINE	Unused product should be disposed of at an approved facility in accordance with federal, state and local regulations.		
ACCIDENTAL RELEASE:	Clean up spills immediately, observing precautions in Section 8 - "Exposure Controls / Personal Protection". Remove or decontaminate all residues in accordance with federal, state and local regulations.		
SI	ECTION 14: TR	ANSPORT INFORMATION	
Component 1 or Formulation 1:	Ipratropium Bror	mide 0.02%	
US Department of Transportation Proper Shipping Name:	Not Regulated		
IATA/ICAO Proper Shipping Name:	Not Regulated		
IMDG Proper Shipping Name:	Not Regulated		
RQ: None	Marine Pollutant	: No	
SE	CTION 15: REC	GULATORY INFORMATION	
EC PACKAGING AND LABELING FOR	SUPPLY:	Not applicable.	
OTHER LEGISLATION:		Not regulated.	
	SECTION 16:	OTHER INFORMATION	
REVISION DATE 02-01-2017			
REVISION DATE: 07-22-2004 REVISION DATE: 03-10-2014 REVISION DATE: 06-19-2014 REVISION DATE: 02-04-2015	SUPER SUPER	SEDES: 01-23-2003 SEDES: 07-22-2004 SEDES: 03-10-2014 SEDES: 06-19-2014	
Safety Data Sheet	F	Page 3 of 4	Nephron Pharmaceuticals Corporation

REVISION DATE: 02-01-2017

SUPERSEDES: 02-04-2015

TO THE BEST OF OUR KNOWLEDGE THE INFORMATION CONTAINED HEREIN IS ACCURATE AS OF THE DATE HEREOF. ANY DETERMINATION AS TO THE SUITABILITY OF THE PRODUCT FOR ANY PARTICULAR PURPOSE, ITS SAFE USE OR DISPOSAL, SHALL BE THE RESPONSIBILITY OF THE USER. THE INFORMATION CONTAINED HEREIN IS IN NO WAY INTENDED TO SUPPLEMENT, MODIFY, OR SUPERSEDE THE INFORMATION PROVIDED IN THE PRODUCT PACKAGE INSERT WITH RESPECT TO THE USE OF THE PRODUCT FOR MEDICAL PURPOSES. PLEASE REFER TO THE PRODUCT PACKAGE INSERT FOR INFORMATION REGARDING THE USE OF THE PRODUCT FOR MEDICAL PURPOSES.